169 related articles for article (PubMed ID: 28454366)
21. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.
Díaz R; Aparicio J; Molina J; Palomar L; Giménez A; Ponce J; Segura A; Gómez-Codina J
Med Oncol; 2006; 23(3):347-57. PubMed ID: 17018892
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a Novel Immune Gene Signature with Profound Prognostic Value in Colorectal Cancer: A Model of Cooperativity Disorientation Created in the Process from Development to Cancer.
An N; Shi X; Zhang Y; Lv N; Feng L; Di X; Han N; Wang G; Cheng S; Zhang K
PLoS One; 2015; 10(9):e0137171. PubMed ID: 26325386
[TBL] [Abstract][Full Text] [Related]
23. Multi-Size Deep Learning Based Preoperative Computed Tomography Signature for Prognosis Prediction of Colorectal Cancer.
Li CH; Cai D; Zhong ME; Lv MY; Huang ZP; Zhu Q; Hu C; Qi H; Wu X; Gao F
Front Genet; 2022; 13():880093. PubMed ID: 35646105
[No Abstract] [Full Text] [Related]
24. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
25. The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.
Sun F; Liang W; Qian J
Mol Med Rep; 2019 Oct; 20(4):3583-3596. PubMed ID: 31432188
[TBL] [Abstract][Full Text] [Related]
26. Identification of a five-gene signature with prognostic value in colorectal cancer.
Sun G; Li Y; Peng Y; Lu D; Zhang F; Cui X; Zhang Q; Li Z
J Cell Physiol; 2019 Apr; 234(4):3829-3836. PubMed ID: 30132881
[TBL] [Abstract][Full Text] [Related]
27. Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer.
Zhu J; Zhang Y; Zhao Y; Zhang J; Hao K; He H
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765243
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Yu X; Li Z; Yu J; Chan MT; Wu WK
Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
30. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
31. Cancer stem cell associated eight gene-based signature predicts clinical outcomes of colorectal cancer.
Dong C; Cui D; Liu G; Xu H; Peng X; Duan J; Liu L
Oncol Lett; 2019 Jan; 17(1):442-449. PubMed ID: 30655785
[TBL] [Abstract][Full Text] [Related]
32. Large-Scale Analysis of Gene Expression Data Reveals a Novel Gene Expression Signature Associated with Colorectal Cancer Distant Recurrence.
Alajez NM
PLoS One; 2016; 11(12):e0167455. PubMed ID: 27935967
[TBL] [Abstract][Full Text] [Related]
33. Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer.
Liu D
FEBS J; 2016 Aug; 283(16):3115-33. PubMed ID: 27376509
[TBL] [Abstract][Full Text] [Related]
34. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.
Fan Q; Liu B
J Cell Biochem; 2018 Apr; 119(4):3574-3585. PubMed ID: 29227531
[TBL] [Abstract][Full Text] [Related]
36. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
37. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
38. Genome-Wide Analysis Reveals Hypoxic Microenvironment Is Associated With Immunosuppression in Poor Survival of Stage II/III Colorectal Cancer Patients.
Chen YF; Yu ZL; Lv MY; Zheng B; Tan YX; Ke J; Liu XH; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Front Med (Lausanne); 2021; 8():686885. PubMed ID: 34211990
[No Abstract] [Full Text] [Related]
39. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
Front Oncol; 2022; 12():883437. PubMed ID: 35719949
[TBL] [Abstract][Full Text] [Related]
40. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Nakayama G; Tanaka C; Uehara K; Mashita N; Hayashi N; Kobayashi D; Kanda M; Yamada S; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Ando Y; Kodera Y
Cancer Chemother Pharmacol; 2014 Apr; 73(4):847-55. PubMed ID: 24577566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
